Axicabtagene ciloleucel, known by the brand name Yescarta, has been accepted for treating adults with two types of blood cancer.

The launch of Almirall’s eczema treatment, Ebglyss (lebrikizumab), generated $22 million in sales across initial European markets, while Ilumetri (tildrakizumab) for psoriasis saw sales rise 24.8% ...

Eli Lilly (NYSE:LLY) is scheduled to announce Q3 earnings results on Wednesday, October 30th, before market open. Analysts expect profit of $1.47 per share on revenue of $12.12B (+27.7% Y/Y).

On Friday, Eli Lilly and Company (NYSE:LLY) revealed new results from the Phase 3b ADapt study of Ebglyss (lebrikizumab), ...

Patients in this study saw improvements in difficult-to-treat areas when treated with Ebglyss. With Ebglyss, 57% of patients in Week 16 and 60% in Week 24 who had previously been treated with ...

Warnings - Do not use EBGLYSS if you are allergic to lebrikizumab-lbkz or to any of the ingredients in EBGLYSS. See the Patient Information leaflet that comes with EBGLYSS for a complete list of ...

New results show Eli Lilly (NYSE: LLY) Ebglyss (lebrikizumab-lbkz) improved skin (including hand and face) and itch among patients with moderate-to-severe atopic dermatitis (eczema) who were ...

MADISON, N.J.--(BUSINESS WIRE)--LEO Pharma Inc., a global leader in medical dermatology, will present a comprehensive catalog of new data around investigational delgocitinib cream in the treatment of ...

Other systematic therapies for AD include Ebglyss (lebrikizumab), Cibinqo (abrocitinib) and Rinvoq (upadacitinib).